The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.
The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.
The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.
The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The new formulation includes minoxidil, finasteride, redensyl, caffeine, and propacil, and removes alcohol. The user is concerned about potential hair shedding due to the change in ingredients.
The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.
An 18-year-old experiencing hair loss and seborrheic dermatitis has tried finasteride, dutasteride, and various shampoos without success. They are considering anti-androgens like RU58841 and KX-826 for oil control and dandruff reduction.
Most people using finasteride, minoxidil, or dutasteride for hair loss experience maintenance or regrowth, but they often don't discuss it publicly. Online forums may not accurately represent the typical success rates, as satisfied users rarely share their positive outcomes.
A 19-year-old male has been using finasteride and minoxidil for nearly two years but continues to experience hairline recession. He is considering switching to dutasteride and exploring options like hair systems and potential future hair transplants.
The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.
The user experienced a receding hairline and tried minoxidil, which may have slowed the process but caused puffy eyes. They are hesitant to use finasteride and suspect oily dandruff might be an aggravator.
Using a blunt tip syringe is an effective method for applying liquid topicals like minoxidil and RU58841, especially for those with thick or long hair experiencing diffuse thinning. The user found significant hair regrowth and increased density after using these topicals for less than three months.
The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.
A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.
The conversation discusses the role of DHT in male hair loss and the effectiveness of treatments like Finasteride, which reduces DHT, and RU58841, which blocks DHT from binding to scalp receptors. The user debates the trade-offs between maintaining hair and having a healthy endocrine system, suggesting RU58841 might allow for both.
RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
A user is making a 2-Deoxy-D-ribose solution and asks if it can be put into an oil instead of a gel, considering adding hydrocortisone and retinoic acid. They seek advice on the best carrier oil for hair growth.
The user is using dutasteride, finasteride, and RU58841 for hair loss but is allergic to minoxidil. Suggestions include dropping finasteride, increasing dutasteride dosage, and considering alternatives like microneedling, laser treatments, scalp massage, and supplements.
The conversation compares Finasteride and Dutasteride for hair loss treatment, discussing their effectiveness and side effects. Users share personal results and consider combining treatments like Dutasteride with RU58841.
User is using a topical solution with .1% finasteride, 6% minoxidil, and .0125% tretinoin for hair loss, along with a .25 derma roller once a week. They are concerned about the necessity and potential side effects of using the derma roller.
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.